{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:50:37Z","timestamp":1790268637281,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"am","delay-in-days":227,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R43ES031038"],"award-info":[{"award-number":["R43ES031038"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R41GM131433-01A1"],"award-info":[{"award-number":["R41GM131433-01A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R44GM122196-02A1"],"award-info":[{"award-number":["R44GM122196-02A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000064","name":"National Center for Complementary and Alternative Medicine","doi-asserted-by":"publisher","award":["3R43AT010585-01S1"],"award-info":[{"award-number":["3R43AT010585-01S1"]}],"id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cbpa.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T01:27:11Z","timestamp":1626398831000},"page":"74-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Recent advances in drug repurposing using machine learning"],"prefix":"10.1016","volume":"65","author":[{"given":"Fabio","family":"Urbina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-8882","authenticated-orcid":false,"given":"Ana C.","family":"Puhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2021.06.001_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2021.06.001_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.cbpa.2021.06.001_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A\u00a0bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cbpa.2021.06.001_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11095-019-2671-y","article-title":"Repurposing approved drugs as inhibitors of Kv7.1 and Nav1.8 to treat pitt hopkins syndrome","volume":"36","author":"Ekins","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib5","first-page":"421","article-title":"Parkinson\u2019s disease drug development since 1999: a story of repurposing and relative success","volume":"11","author":"Boucherie","year":"2021","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.cbpa.2021.06.001_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020941494","article-title":"Repurposing of medications for pulmonary arterial hypertension","volume":"10","author":"Toshner","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.cbpa.2021.06.001_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1568026615666150112103510","article-title":"Computational and experimental advances in drug repositioning for accelerated therapeutic stratification","volume":"15","author":"Shameer","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cbpa.2021.06.001_bib8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.drudis.2020.03.019","article-title":"Deja vu: stimulating open drug discovery for SARS-CoV-2","volume":"25","author":"Ekins","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cbpa.2021.06.001_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In silico repositioning of approved drugs for rare and neglected diseases","volume":"16","author":"Ekins","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cbpa.2021.06.001_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A\u00a0survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.cbpa.2021.06.001_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drudis.2012.11.005","article-title":"Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates","volume":"18","author":"Southan","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cbpa.2021.06.001_bib12","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1021\/acsomega.0c05996","article-title":"Repurposing the Ebola and marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in\u00a0vitro activity against SARS-CoV-2 and potential mechanisms","volume":"6","author":"Puhl","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.cbpa.2021.06.001_sref13","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2021.06.001_sref14","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cbpa.2021.06.001_bib15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/cid\/ciaa940","article-title":"The emergence of baricitinib: a story of tortoises versus hares","volume":"72","author":"Lenz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2021.06.001_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of baricitinib in patients with moderate to severe coronavirus disease 2019","volume":"72","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2021.06.001_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240079","article-title":"Biochemical screening for SARS-CoV-2 main protease inhibitors","volume":"15","author":"Coelho","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2021.06.001_bib18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/2472555220963667","article-title":"High-throughput screening for drugs that inhibit papain-like protease in SARS-CoV-2","volume":"25","author":"Smith","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.cbpa.2021.06.001_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12033-021-00299-7","article-title":"Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARS-COV-2 main protease (3CLpro)","volume":"63","author":"Rothan","year":"2021","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1021\/acsptsci.0c00122","article-title":"Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 nucleocapsid","volume":"3","author":"Gorshkov","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.cbpa.2021.06.001_bib21","doi-asserted-by":"crossref","first-page":"592737","DOI":"10.3389\/fphar.2020.592737","article-title":"Drug\u00a0repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib22","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.cbpa.2021.06.001_sref23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A\u00a0SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2021.06.001_sref24","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe9403","article-title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms","volume":"370","author":"Gordon","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2021.06.001_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A\u00a0randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2021.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.2196\/21758","article-title":"Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: single-center retrospective chart review","volume":"22","author":"Roomi","year":"2020","journal-title":"J\u00a0Med Internet Res"},{"key":"10.1016\/j.cbpa.2021.06.001_sref27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/acsptsci.0c00131","article-title":"Virtual and in\u00a0vitro antiviral screening revive therapeutic drugs for COVID-19","volume":"3","author":"Bocci","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.cbpa.2021.06.001_bib28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.cbpa.2021.06.001_bib29","doi-asserted-by":"crossref","first-page":"104419","DOI":"10.1016\/j.meegid.2020.104419","article-title":"Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein","volume":"85","author":"Feng","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib30","article-title":"Discovery of drug-like ligands for the Mac1 domain of SARS-CoV-2 Nsp3","author":"Virdi","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cbpa.2021.06.001_bib31","volume":"2020","author":"Roskoski","year":"2020"},{"key":"10.1016\/j.cbpa.2021.06.001_bib32","doi-asserted-by":"crossref","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/2168479017751404","article-title":"Anticancer drug prescription patterns in Japan: future directions in cancer therapy","volume":"52","author":"Shibata","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.cbpa.2021.06.001_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.chembiol.2019.02.018","article-title":"Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries","volume":"26","author":"Moret","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nbt.3374","article-title":"Comprehensive characterization of the published kinase inhibitor set","volume":"34","author":"Elkins","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib36","doi-asserted-by":"crossref","first-page":"D995","DOI":"10.1093\/nar\/gkw1072","article-title":"Pharos: collating protein information to shed light on the druggable genome","volume":"45","author":"Nguyen","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2021.06.001_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd.2017.252","article-title":"Glimmers in illuminating the druggable genome","volume":"17","author":"Rodgers","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2021.06.001_bib39","doi-asserted-by":"crossref","first-page":"D529","DOI":"10.1093\/nar\/gkaa853","article-title":"The Dark Kinase Knowledgebase: an online compendium of knowledge and experimental results of understudied kinases","volume":"49","author":"Berginski","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib40","doi-asserted-by":"crossref","first-page":"15826","DOI":"10.1038\/s41598-020-72869-9","article-title":"PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor","volume":"10","author":"Tamir","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2021.06.001_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cels.2017.11.001","article-title":"The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations","volume":"6","author":"Keenan","year":"2018","journal-title":"Cell Syst"},{"key":"10.1016\/j.cbpa.2021.06.001_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","article-title":"A\u00a0multi-center study on the reproducibility of drug-response assays in mammalian cell lines","volume":"9","author":"Niepel","year":"2019","journal-title":"Cell Syst"},{"key":"10.1016\/j.cbpa.2021.06.001_bib43","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/0008-5472.CAN-09-2877","article-title":"The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2","volume":"70","author":"Zimmer","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc2044","article-title":"The Connectivity Map: a new tool for biomedical research","volume":"7","author":"Lamb","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cbpa.2021.06.001_bib45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2021.06.001_bib46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A\u00a0next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2021.06.001_bib47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fchem.2020.00296","article-title":"Exploring the use of compound-induced transcriptomic data generated from cell lines to predict compound activity toward molecular targets","volume":"8","author":"Baillif","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.cbpa.2021.06.001_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41467-019-13807-w","article-title":"De novo generation of hit-like molecules from gene expression signatures using artificial intelligence","volume":"11","author":"Mendez-Lucio","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2021.06.001_sref49","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.chembiol.2019.08.007","article-title":"Chemogenomic analysis of the druggable kinome and its application to repositioning and lead identification studies","volume":"26","author":"Ravikumar","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005678","article-title":"Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors","volume":"13","author":"Cichonska","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib51","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.jcim.8b00640","article-title":"Drug discovery maps, a machine learning model that visualizes and predicts kinome-inhibitor interaction landscapes","volume":"59","author":"Janssen","year":"2019","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.cbpa.2021.06.001_bib52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/acs.jmedchem.6b01611","article-title":"Profiling prediction of kinase inhibitors: toward the virtual assay","volume":"60","author":"Merget","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cbpa.2021.06.001_bib53","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1021\/acs.jcim.9b00798","article-title":"Machine learning models based on molecular fingerprints and an extreme gradient boosting method lead to the discovery of JAK2 inhibitors","volume":"59","author":"Yang","year":"2019","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.cbpa.2021.06.001_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201800031","article-title":"Development of ligand-based big data deep neural network models for virtual screening of large compound libraries","volume":"37","author":"Xiao","year":"2018","journal-title":"Mol Inform"},{"key":"10.1016\/j.cbpa.2021.06.001_bib55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11030-014-9561-3","article-title":"Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery","volume":"19","author":"Fang","year":"2015","journal-title":"Mol Divers"},{"key":"10.1016\/j.cbpa.2021.06.001_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acs.jcim.7b00300","article-title":"Identification of novel aurora kinase A (AURKA) inhibitors via hierarchical ligand-based virtual screening","volume":"58","author":"Kong","year":"2018","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.cbpa.2021.06.001_bib57","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib58","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1021\/acs.jmedchem.9b00855","article-title":"Deep learning enhancing kinome-wide polypharmacology profiling: model construction and experiment validation","volume":"63","author":"Li","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cbpa.2021.06.001_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061318","article-title":"Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties","volume":"8","author":"Menden","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2021.06.001_bib60","article-title":"A\u00a0novel drug repurposing approach for non-small cell lung cancer using deep learning","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2021.06.001_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006619","article-title":"Rational discovery of dual-indication multi-target PDE\/kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology","volume":"15","author":"Lim","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib62","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1038\/s41598-020-70026-w","article-title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","volume":"10","author":"Anderson","year":"2020","journal-title":"Sci Rep"},{"issue":"Suppl 7","key":"10.1016\/j.cbpa.2021.06.001_bib63","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2164-15-S7-S2","article-title":"Computational identification of multi-omic correlates of anticancer therapeutic response","volume":"15","author":"Stetson","year":"2014","journal-title":"BMC Genom"},{"key":"10.1016\/j.cbpa.2021.06.001_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S37929","article-title":"Clinical epidemiology of Alzheimer\u2019s disease: assessing sex and gender differences","volume":"6","author":"Mielke","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5607\/en.2013.22.2.84","article-title":"An update of animal models of Alzheimer disease with a reevaluation of plaque depositions","volume":"22","author":"Lee","year":"2013","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bcp.12621","article-title":"Emerging drug targets for Abeta and tau in Alzheimer's disease: a systematic review","volume":"80","author":"West","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cbpa.2021.06.001_sref67","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41467-021-21330-0","article-title":"Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2021.06.001_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","article-title":"Increased level of active GSK-3beta in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration","volume":"33","author":"Leroy","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbr.2017.11.015","article-title":"Diabetes mellitus and Alzheimer\u2019s disease: GSK-3beta as a potential link","volume":"339","author":"Zhang","year":"2018","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib71","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pneurobio.2006.07.006","article-title":"The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways","volume":"79","author":"Beurel","year":"2006","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2121-2-12","article-title":"Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity","volume":"2","author":"Turenne","year":"2001","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0304-3940(92)90839-Y","article-title":"Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments","volume":"148","author":"Ishiguro","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cbpa.2021.06.001_bib74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0304-3940(92)90774-2","article-title":"Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase","volume":"147","author":"Hanger","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cbpa.2021.06.001_bib75","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0960-9822(00)00246-3","article-title":"Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells","volume":"4","author":"Lovestone","year":"1994","journal-title":"Curr Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib76","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1074\/jbc.M610708200","article-title":"GSK3beta activity modifies the localization and function of presenilin 1","volume":"282","author":"Uemura","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cbpa.2021.06.001_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI64516","article-title":"Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes","volume":"123","author":"Ly","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cbpa.2021.06.001_bib78","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.2174\/1381612823666170714141450","article-title":"GSK3 inhibitors in the therapeutic development of diabetes, cancer and neurodegeneration: past, present and future","volume":"23","author":"Maqbool","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2021.06.001_bib79","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-15-2240","article-title":"Molecular pathways: revisiting glycogen synthase kinase-3beta as a target for the treatment of cancer","volume":"23","author":"Walz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2021.06.001_bib80","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-190256","article-title":"Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"69","author":"Matsunaga","year":"2019","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.cbpa.2021.06.001_bib81","doi-asserted-by":"crossref","first-page":"19977","DOI":"10.1038\/s41598-019-56461-4","article-title":"9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer","volume":"9","author":"Kuroki","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2021.06.001_bib82","doi-asserted-by":"crossref","first-page":"26551","DOI":"10.1021\/acsomega.0c03302","article-title":"Machine learning for discovery of GSK3\u03b2 inhibitors","volume":"5","author":"Vignaux","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.cbpa.2021.06.001_bib83","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/ci800143n","article-title":"Global Bayesian models for the prioritization of antitubercular agents","volume":"48","author":"Prathipati","year":"2008","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.cbpa.2021.06.001_bib84","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1039\/b917766c","article-title":"A\u00a0collaborative database and computational models for tuberculosis drug discovery","volume":"6","author":"Ekins","year":"2010","journal-title":"Mol BioSystems"},{"key":"10.1016\/j.cbpa.2021.06.001_bib85","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1039\/C0MB00104J","article-title":"Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis","volume":"6","author":"Ekins","year":"2010","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.cbpa.2021.06.001_bib86","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nature09107","article-title":"Thousands of chemical starting points for antimalarial lead identification","volume":"465","author":"Gamo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2021.06.001_bib87","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.chembiol.2013.01.011","article-title":"Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery","volume":"20","author":"Ekins","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063240","article-title":"Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event bayesian models","volume":"8","author":"Ekins","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cbpa.2021.06.001_bib89","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tube.2013.12.001","article-title":"Bayesian models for screening and TB mobile for target inference with Mycobacterium tuberculosis","volume":"94","author":"Ekins","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.cbpa.2021.06.001_bib90","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.molpharmaceut.8b00083","article-title":"Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery","volume":"15","author":"Lane","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cbpa.2021.06.001_sref91","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A\u00a0deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2021.06.001_bib92","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fphar.2019.00913","article-title":"Identification of novel antibacterials using machine learning techniques","volume":"10","author":"Ivanenkov","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cbpa.2021.06.001_sref93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.chembiol.2018.01.015","article-title":"Repurposing high-throughput image assays enables biological activity prediction for drug discovery","volume":"25","author":"Simm","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2021.06.001_bib94","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41598-018-19767-3","article-title":"Neuroprotective drug for nerve trauma revealed using artificial intelligence","volume":"8","author":"Romeo-Guitart","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2021.06.001_sref95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12936-018-2294-5","article-title":"A\u00a0systematic and prospectively validated approach for identifying synergistic drug combinations against malaria","volume":"17","author":"KalantarMotamedi","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.cbpa.2021.06.001_sref96","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aaz9906","article-title":"The activities of drug inactive ingredients on biological targets","volume":"369","author":"Pottel","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2021.06.001_bib97","doi-asserted-by":"crossref","DOI":"10.1039\/D0CS01065K","article-title":"A critical overview of computational approaches employed for COVID-19 drug discovery","author":"Muratov","year":"2021","journal-title":"Chem Soc Rev."}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593121000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593121000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:48:56Z","timestamp":1761274136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593121000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":97,"alternative-id":["S1367593121000818"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2021.06.001","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in drug repurposing using machine learning","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}